Literature DB >> 16955294

[Acetylsalicylic acid in self-medication of migraine. A pharmacy-based observational study].

H Göbel1, U Gessner, M Petersen-Braun, U Weingärtner.   

Abstract

BACKGROUND: The aim of the study was to investigate the efficacy and tolerability of acetylsalicylic acid in the treatment of acute migraine attacks by self-medication under daily life conditions when bought in a pharmacy and also the ability of patients to self-diagnose correctly.
METHODS: A total of 296 patients were recruited from 156 pharmacies and recorded up to 3 migraine attacks. Following an advisory discussion the pharmacists gave a questionnaire to persons who had purchased acetylsalicylic acid (Aspirin Migraine) in the pharmacy to treat migraine. A total of 578 questionnaires containing 36 questions about demographic details, headache phenotype, medical history, efficacy over 2 h and tolerability of the preparation were analyzed.
RESULTS: The IHS criteria (1988) for migraine were identified correctly by 92.7% of the patients. In 66.3% of the attacks, the intensity of the headache was reported as severe. In 60% of the documented attacks, a decrease from severe or moderate to mild or no headache was recorded after medication, and freedom from headache was achieved in 35.8%. The effect was reproducible over 3 migraine attacks. Nausea, photophobia and phonophobia were reduced by 71-86% compared to the baseline level. Side-effects were reported twice as often by the participants in response to closed questions than to open questions (16.6 vs. 8.3%).
CONCLUSION: A high percentage of migraine patients are capable of diagnosing their condition themselves when they seek advice in a pharmacy. The data on efficacy confirm the results from controlled clinical studies. The same parameters as those used in controlled clinical studies can also be recorded in pharmacy-based observational studies, therefore, the safety and tolerability of the medication can be recorded under real conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16955294     DOI: 10.1007/s00482-006-0499-y

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  9 in total

1.  Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine.

Authors:  A Eikermann; H C Diener
Journal:  Cephalalgia       Date:  2003-06       Impact factor: 6.292

2.  Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.

Authors: 
Journal:  Cephalalgia       Date:  1988       Impact factor: 6.292

3.  Migraine in the United States: epidemiology and patterns of health care use.

Authors:  R B Lipton; A I Scher; K Kolodner; J Liberman; T J Steiner; W F Stewart
Journal:  Neurology       Date:  2002-03-26       Impact factor: 9.910

4.  Migraine diagnosis and treatment: results from the American Migraine Study II.

Authors:  R B Lipton; S Diamond; M Reed; M L Diamond; W F Stewart
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

5.  Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.

Authors:  R Lange; J A Schwarz; M Hohn
Journal:  Cephalalgia       Date:  2000-09       Impact factor: 6.292

6.  Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks.

Authors:  H C Diener; G Bussone; H de Liano; A Eikermann; R Englert; T Floeter; V Gallai; H Göbel; E Hartung; M D Jimenez; R Lange; G C Manzoni; G Mueller-Schwefe; G Nappi; L Pinessi; J Prat; F M Puca; F Titus; M Voelker
Journal:  Cephalalgia       Date:  2004-11       Impact factor: 6.292

7.  Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms.

Authors:  H C Diener; A Eikermann; U Gessner; H Göbel; G Haag; R Lange; A May; G Müller-Schwefe; M Voelker
Journal:  Eur Neurol       Date:  2004-07-05       Impact factor: 1.710

8.  Patient drug attributions and postmarketing surveillance.

Authors:  S Fisher; S G Bryant; T A Kent; J E Davis
Journal:  Pharmacotherapy       Date:  1994 Mar-Apr       Impact factor: 4.705

9.  [Prevalence of headache syndromes in Germany.].

Authors:  H Göbel; M Petersen-Braun; D Soyka
Journal:  Schmerz       Date:  1993-12       Impact factor: 1.107

  9 in total
  1 in total

1.  Impact of the Neck and/or Shoulder Pain on Self-reported Headache Treatment Responses - Results From a Pharmacy-Based Patient Survey.

Authors:  Charly Gaul; Heidemarie Gräter; Thomas Weiser; Martin C Michel; Anette Lampert; Manuel Plomer; Stefanie Förderreuther
Journal:  Front Neurol       Date:  2022-07-18       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.